Ovarian Cancer

Elizabeth K. Lee, MD, discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer.

Hyun Woong Cho, MD, PhD, explains the rationale for assessing niraparib/bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Fiona Simpkins, MD, discusses the use of cyclin E1 positivity as a biomarker of azenosertib response in platinum-resistant ovarian cancer.

Hyun-Woong Cho, MD, PhD, highlights the efficacy of niraparib/bevacizumab as maintenance therapy in platinum-sensitive, recurrent ovarian cancer.

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

SON-1010 plus atezolizumab was safe and showed clinical activity in platinum-resistant ovarian cancer and other advanced solid tumors.

Tashanna K. Myers, MD, discusses the importance of telling patients with ovarian cancer about the HRQOL outcomes associated with mirvetuximab soravtansine.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

Orca-T boosts cGVHD-free survival in hematologic malignancies, cilta-cel continues to impress in CARTITUDE-4, and more.

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

Toon Van Gorp, MD, PhD, discusses the significance of mirvetuximab soravtansine as treatment for FRα-positive, platinum-resistant ovarian cancer.

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss ongoing research and areas of potential investigation in ovarian cancer.

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss updates in ovarian cancer from the 2025 SGO Annual Meeting.

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss other potential roles for mirvetuximab soravtansine in ovarian cancer.

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on patient-reported outcome data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on final overall survival data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Alexander B. Olawaiye, MD, discusses future research that could inform the use of afuresertib plus paclitaxel in platinum-resistant ovarian cancer.

Melissa M. Hardesty, MD, discusses OS and subgroup data from the OVARIO study of niraparib and bevacizumab maintenance in newly diagnosed ovarian cancer.

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss current treatment approached in platinum-resistant ovarian cancer.

Relacorilant plus nab-paclitaxel demonstrated improved PFS and OS in platinum-resistant ovarian cancer.

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

Tashanna K. Myers, MD, discusses HRQOL findings in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine in MIRASOL.

TILT-123 plus pembrolizumab was active in platinum-resistant/refractory ovarian cancer in the phase 1a PROTA trial and the phase 1b portion is ongoing.

The addition of tumor treating fields to paclitaxel did not lead to a statistically significant overall survival improvement in platinum-resistant ovarian cancer.